CN115154489B - Multi-flora composite preparation and culture for treating sheep cheese lymphadenitis - Google Patents
Multi-flora composite preparation and culture for treating sheep cheese lymphadenitis Download PDFInfo
- Publication number
- CN115154489B CN115154489B CN202210633339.XA CN202210633339A CN115154489B CN 115154489 B CN115154489 B CN 115154489B CN 202210633339 A CN202210633339 A CN 202210633339A CN 115154489 B CN115154489 B CN 115154489B
- Authority
- CN
- China
- Prior art keywords
- culture
- lymphadenitis
- flora
- preparation
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a multi-flora compound preparation and a culture for treating sheep cheese lymphadenitis, and belongs to the technical field of sheep infectious disease treatment. The multi-flora compound preparation for treating sheep cheese lymphadenitis comprises bifidobacterium (bifidobacteria sp.), lactobacillus acidophilus (lactobacillus acidophilus) and lactobacillus reuteri (lactobacillus reuteri); the culture solution of each bacterium is sterilized and then mixed to prepare the pustule peripheral injection preparation which is combined with the multi-flora compound preparation to effectively treat the sheep cheese lymphadenitis.
Description
Technical Field
The invention belongs to the technical field of sheep infectious disease treatment, and particularly relates to a multi-flora compound preparation and a culture for treating sheep cheese lymphadenitis.
Background
The cheese lymphadenitis (Caseous lymphadenitis, CLA) is prepared from pseudotuberculosis corynebacteriaCorynebacterium pseudotuberculosis, C. pseudotuberculosis, C.pCPTB) causes a chronic suppurative infectious disease in goats and sheep. C.p is gram positive, non-capsular, non-motile, pilus and polymorphic facultative intracellular parasitic bacteria, mainly causes surface type cheese lymphadenitis of sheep, infected sheep often presents lymph node swelling at head and neck, and pustules and pustule rupture phenomenon occur at the later stage of infection, and the discharged pus can seriously pollute surrounding soil, water source, feed, pasture and equipment, thereby causing further transmission of pathogen. As CLA progresses slowly to form lesions, it will lead to persistent infections and life-long toxic states. The disease is prevalent throughout the world and has become one of the epidemic diseases that lead to significant economic losses in the sheep industry, such as: the wool yield is reduced, the milk yield is reduced, the growth is slow, and the carcass is abandoned and degraded in meat quarantine and the like.
The common treatment mode of CLA is antibiotic treatment, but the corynebacterium pseudotuberculosis is facultative intracellular parasitic bacteria, which has a protective effect on some common antibiotics, and the antibiotics have high treatment cost and poor treatment effect. Treatment at the individual level further includes: draining pus, cleaning, sterilizing with 10% iodine solution or removing abscess by operation. However, there are some drawbacks to this therapy, such as the presence of a large amount of pathogenic microorganisms in the pus discharged from the body surface during surgery, which can cause the pathogens to contaminate the surrounding environment if not cleaned or not cleaned in time, further increasing the risk of infection. In addition, the lesion presents granulomatous lesions at the early stage of infection of the sick sheep, and the operation toxin expelling frequently recurs and is difficult to radically cure.
Therefore, there is a need to develop an agent effective in inhibiting or controlling CLA, thereby preventing the spread of Corynebacterium pseudotuberculosis and the outbreak of CLA.
Disclosure of Invention
The invention discloses a multi-flora composite preparation and a culture for treating sheep cheese lymphadenitis, which can effectively inhibit corynebacterium pseudotuberculosis and has obvious treatment effect on sheep cheese lymphadenitis.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
a multi-flora compound preparation for treating sheep cheese lymphadenitis comprises BifidobacteriumBifidobacterium sp.) 202210 Lactobacillus acidophilusLactobacillus acidophilus) 202211 and Lactobacillus reuteri ]Lactobacillus reuteri）202212；
The bifidobacterium is preserved in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) for 2022, 04 month and 26 days, the preservation place is North Xili No. 1, 3 in the Korean region of Beijing, the preservation number is CGMCC No.24771,
lactobacillus acidophilus is preserved in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) for 2022, 04 month and 26 days, with a preservation place of Beijing, chaoyang area, north Xiyi No. 1, 3, and a preservation number of CGMCC No.24772,
lactobacillus reuteri is preserved in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) for 2022, 04 month and 26 days, and the preservation place is North Xili No. 1, 3 in the Korean region of Beijing, and the preservation number is CGMCC No.24773.
Preferably, bifidobacterium, lactobacillus acidophilus and lactobacillus reuteri are mixed in the same amount.
Preferably, the concentration of each bacterium is 10 7 CFU/mL。
The bifidobacterium, the lactobacillus acidophilus and the lactobacillus reuteri can participate in the immune response of a host by competing with pathogens of intestinal microbiota and stimulating mucosal immunity, and extracellular polysaccharide can enhance the immunoregulatory function of the host; and the metabolite thereof can effectively inhibit pathogenic bacteria.
A multi-flora culture for treating sheep cheese lymphadenitis is a degerming mixture of various bacterial culture solutions in the multi-flora compound preparation.
Preferably, the preparation method of the culture comprises the following steps:
inoculating bifidobacterium, lactobacillus acidophilus and lactobacillus reuteri respectively into MRS liquid culture medium, anaerobically culturing at 37 ℃ for 32 hours, centrifuging, and taking supernatant to obtain each bacterial culture solution;
mixing the culture solutions in equal volume, filtering, sterilizing, and making into injection.
Preferably, the centrifugation conditions are 5000r/min for 20min,
the filtration step used a 0.22 μm filter.
The bifidobacterium, lactobacillus acidophilus and lactobacillus reuteri can produce various bactericidal compounds including organic acid, diacetyl, hydrogen peroxide, bacteriocin and the like, and can directly kill pathogenic bacteria or change the growing microenvironment of the pathogenic bacteria so as to inhibit the reproduction of the pathogenic bacteria, so that several bacteria are cultivated, and the sterile supernatant of the culture solution is taken and injected to the periphery of the pustule so as to quickly inhibit the pseudotuberculosis corynebacteria in the pustule.
A combined preparation for treating sheep cheese lymphadenitis comprises an oral preparation and a pustular peripheral injection preparation;
the oral preparation is the multi-flora composite preparation,
the preparation for pericycle injection of the pustule is the culture.
The oral preparation and the pustule peripheral injection preparation are combined, so that the treatment effect can be effectively ensured.
In summary, compared with the existing treatment method and effects of sheep CLA caused by the corynebacterium pseudotuberculosis, the invention has the following advantages and effects:
firstly, utilizing antibacterial components in cultures of bifidobacterium, lactobacillus acidophilus and lactobacillus reuteri, such as hydrogen peroxide, bacteriocin or organic acid, and the like, changing the microenvironment of pathogenic bacteria and inhibiting the growth of the pathogenic bacteria, and solving the defect that the pseudotuberculosis corynebacterium has immune escape function on antibiotics as intracellular parasitic bacteria of macrophages; meanwhile, the immunity of the host against pathogenic bacteria can be improved, and the anti-infection capability is enhanced.
Second, some traditional surgical therapies present a risk of bacterial spread and further outbreak of infection. The oral preparation and the pustule peripheral injection preparation can inhibit further propagation deterioration of the corynebacterium pseudotuberculosis in the organism and reduce the risk of environmental pollution caused by pustule rupture.
In addition, the invention lays a theoretical foundation for researching the action mechanism of lactobacillus on the corynebacterium pseudotuberculosis.
Drawings
FIG. 1 shows colony morphology characteristics of partially isolated strains.
FIG. 2 shows the results of nucleic acid gel electrophoresis of partially isolated strains;
wherein M is DL 5000 marker,1 is negative control, and 2-4 is sample.
FIG. 3 shows a 16S rRNA sequence phylogenetic tree of partially isolated strains;
wherein 1 is bifidobacterium, LAB-1 is lactobacillus acidophilus, and LAB-3 is lactobacillus reuteri.
FIG. 4 shows colony morphology of pathogenic bacteria on different media.
FIG. 5 shows the results of nucleic acid gel electrophoresis of pathogenic bacteria;
wherein M is DL 2000 marker,1 is sample, and 2 is negative control.
FIG. 6 shows the in vitro bacteriostasis results of strain 1, LAB-3 culture supernatants on Mycobacterium pseudotuberculosis;
wherein A is an experimental group and B is a control group.
FIG. 7 shows the in vivo bacteriostasis of strain 1, LAB-3 and culture supernatants thereof against Mycobacterium pseudotuberculosis;
wherein A is an experimental group and B is a control group.
Description of the embodiments
The following description of the embodiments of the present invention will be made clearly and completely, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
In the examples MRS medium was purchased from Qingdao high technology Industrial park Haibo Biotechnology Co., ltd; bacterial genomic DNA extraction kits were purchased from the astronomical biochemistry sciences ltd; TRYPTONE, YEAST EXTRACT, available from ThermoFisher; agar was purchased from BioFrox; naCl was purchased from Duckweed white lion chemical Co.
Example 1 isolation and identification of Strain
Collecting faeces sample from sheep factory in Qinghai province, collecting faeces sample 5 g, and mixing in conical flask containing 50 mL autoclaved physiological saline; diluting with sterilized normal saline at 10 times ratio; the dilution with proper concentration is evenly coated on MRS solid culture medium (containing 2 percent CaCO) 3 ) And (3) performing anaerobic culture by pouring the mixture at 37 ℃.
The culture dish is selected to have a calcium dissolving ring, round bulges, smooth surface, regular edges and milky single colony of suspicious lactobacillus, and is inoculated into a sterile MRS liquid culture medium for anaerobic culture at 37 ℃. The cloning and purification culture of the strain was repeated (FIG. 1).
The purified bacterial liquid and sterilized 50% glycerol are uniformly mixed according to the volume ratio of 1:1, marked and stored in an ultralow temperature refrigerator for standby.
Extracting the total DNA of each bacterium according to the instruction of the bacterial genome DNA extraction kit. The extracted bacterial DNA is used as a template, and bacterial 16S rRNA universal primer is used for gene amplification, an upstream primer 5'-AGAGTTTGATCMTGGCTCAG-3', a downstream primer 5'-GGTTACCTTGTTACGACTT-3' and a target fragment 1465bp.
The PCR reaction conditions are shown in Table 1.
TABLE 1 PCR reaction conditions
The PCR products were subjected to 1% agarose gel electrophoresis (see FIG. 2 for partial results), and after the expected results were met, the products were sequenced and identified. The sequencing results were aligned for homology with known strains in the GenBank database using BLAST and analyzed for species evolution to determine strain species (see FIG. 3 for partial results). The results show that the isolated strains include bifidobacterium, lactobacillus acidophilus, lactobacillus reuteri and the like.
Example 2 in vitro bacteriostatic Effect of lactic acid bacteria cultures on Corynebacterium pseudotuberculosis
1. Separating and identifying bacteria from clinical suspected sheep CLA disease material
Proper amount of pus is taken out through aseptic operation, diluted and mixed evenly, the diluted and mixed pus is evenly coated on a 5% sheep fresh blood agar plate, the mixture is cultured at 37 ℃ for 24-48 h, colony growth characteristics on the plate are carefully observed and recorded, and the colony is dry, opaque, off-white, uneven in edge and protruding in the center, and a narrow beta hemolysis ring is arranged around the colony (figure 4A).
The suspicious colony is picked and purified and cultured continuously: inoculating the strain to a common agar plate, culturing at 37 ℃ for 48 h, and observing a culturing result; off-white, round, drier microcolonies are visible (FIG. 4B). The colony is easy to push and break, and the alcohol burner is different from the crackles of other strains when being burnt by flame.
The extracted bacterial DNA is used as a template, a specific primer CPTB of the corynebacterium pseudotuberculosis is used for gene amplification, an upstream primer 5'-ACCGCACTTTAGTGTGTGTG-3', a downstream primer 5'-TCTCTACGCCGATCTTGTAT-3' and a target fragment 816bp, and PCR reaction conditions are shown in Table 2.
TABLE 2 PCR reaction conditions
The PCR products were subjected to 1% agarose gel electrophoresis and the results showed specific bands at 816 and bp, and the isolated strain was identified as Corynebacterium pseudotuberculosis (FIG. 5).
The isolated and identified strain of example 1 was cultured anaerobically for 32h at 37℃and centrifuged at 5000r/min for 20min, the supernatant was obtained, and the supernatants of the three bacteria were mixed in equal volumes and filtered with a 0.22 μm filter membrane for further use. Placing the isolated and identified corynebacterium pseudotuberculosis in liquid LB for culturing 48 h; after that, 100. Mu.L was added to 5 mL of the sterile LB liquid medium. While experimental group was added with 1 mL example 1 strain culture supernatant and control group was added with 1 mL MRS liquid medium. Culturing at 37deg.C for 48 h, diluting with sterile physiological saline solution ten times, selecting proper concentration, spreading on LB solid medium, culturing at 37deg.C for 48 h, and observing.
The results showed that the experimental group showed no growth of Corynebacterium pseudotuberculosis compared with the control group, demonstrating that the lactobacillus culture had a better bacteriostatic effect on Corynebacterium pseudotuberculosis (FIG. 6).
EXAMPLE 3 in vivo antibacterial Effect of lactic acid bacteria and cultures thereof on Corynebacterium pseudotuberculosis
The method for evaluating the treatment effect of clinical sheep infected with the corynebacterium pseudotuberculosis comprises the following steps of:
clinical diseased sheep neck pustule disease material was collected and bacterial count on LB solid medium was performed as control group. The same amount of each strain was 10 by mixing strain 1 (again named 202210), LAB-1 (again named 202211), LAB-3 x (again named 202212) 7 CFU/mL, then orally treating the sick sheep with a dose of 100 mL/d per sheep, and continuously orally administering 7 d; simultaneously, respectively inoculating the strain 1, the LAB-1 and the LAB-3 into an MRS liquid culture medium, carrying out anaerobic culture at 37 ℃ for 32h, centrifuging at 5000r/min for 20min, mixing the supernatants of the three bacteria in equal volumes,the filtrate was filtered through a 0.22 μm filter and then multi-site injected around the pustule of the affected sheep at doses referenced to the pustule diameter size. Typically per pustule diameter<3 cm, the injection dose is 2 mL/d, 3 d; at a diameter of ≡ 3 cm, the injection dose is 3 mL/d, 3 d consecutive. After 5 d, the pustules at the affected area were collected and bacteria were counted in the same manner.
The results showed a significant reduction in bacterial numbers at the pustules of the diseased sheep after treatment compared to before treatment (fig. 7). The preparation provided by the invention has a good effect of inhibiting pathogenic bacteria from propagating on sheep cheese lymphadenitis caused by corynebacterium pseudotuberculosis clinically.
In the present specification, each embodiment is described in a progressive manner, and each embodiment is mainly described in a different point from other embodiments, and identical and similar parts between the embodiments are all enough to refer to each other.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to the embodiments described above will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (4)
1. A multi-flora culture for treating sheep cheese lymphadenitis is characterized in that,
the culture is a degerming mixture of various bacterial culture solutions in the multi-flora composite preparation;
the preparation method of the culture comprises the following steps:
the bifidobacterium is treatedBifidobacterium sp.) Lactobacillus acidophilusLactobacillus acidophilus) And lactobacillus reuteri @ andLactobacillus reuteri) Respectively inoculating into MRS liquid culture medium, anaerobic culturing at 37deg.C for 32 hr, centrifuging, and collecting supernatant to obtain each strain culture solution;
the preservation number of the bifidobacterium is CGMCC No.24771,
the preservation number of the lactobacillus acidophilus is CGMCC No.24772,
the preservation number of the lactobacillus reuteri is CGMCC No.24773;
mixing the culture solutions of the bacteria in equal volume, filtering and sterilizing to obtain the final product.
2. A multi-flora culture for treating lymphadenitis in sheep according to claim 1, wherein,
the centrifugation condition is that the centrifugation is 5000r/min for 20min,
the filtration was carried out using a 0.22 μm filter.
3. A combined preparation for treating sheep cheese lymphadenitis is characterized in that,
including oral formulations and pustular peripheral injection formulations;
the oral preparation is a multi-flora compound preparation, and comprises bifidobacteriumBifidobacterium sp.) Lactobacillus acidophilusLactobacillus acidophilus) And lactobacillus reuteri @ andLactobacillus reuteri）；
the preservation number of the bifidobacterium is CGMCC No.24771,
the preservation number of the lactobacillus acidophilus is CGMCC No.24772,
the preservation number of the lactobacillus reuteri is CGMCC No.24773;
the concentration of the bacteria is 10 7 CFU/mL；
The peripustule injection formulation is the multi-flora culture of claim 1 or 2.
4. Use of a multi-flora culture according to claim 1 or 2 for the preparation of a formulation for the treatment of sheep's cheese lymphadenitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210633339.XA CN115154489B (en) | 2022-06-06 | 2022-06-06 | Multi-flora composite preparation and culture for treating sheep cheese lymphadenitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210633339.XA CN115154489B (en) | 2022-06-06 | 2022-06-06 | Multi-flora composite preparation and culture for treating sheep cheese lymphadenitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115154489A CN115154489A (en) | 2022-10-11 |
| CN115154489B true CN115154489B (en) | 2023-07-21 |
Family
ID=83485820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210633339.XA Active CN115154489B (en) | 2022-06-06 | 2022-06-06 | Multi-flora composite preparation and culture for treating sheep cheese lymphadenitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115154489B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1800688A1 (en) * | 2004-08-05 | 2007-06-27 | Anidral S.R.L. | Folic acid producing bifidobacterium bacterial strains, formulations and use thereof |
| CN105181963A (en) * | 2015-07-30 | 2015-12-23 | 西北农林科技大学 | Preparation method for ELISA detection kit of goat corynebacterium pseudotuberculosis antibodies |
| CN106176998A (en) * | 2016-07-15 | 2016-12-07 | 湖北省农业科学院畜牧兽医研究所 | A kind of compositions for treating goat skin submental lymph nodes abscess |
| CN110669697A (en) * | 2019-10-31 | 2020-01-10 | 江苏微康生物科技有限公司 | Lactobacillus casei for high yield of short-chain fatty acid, culture method and application thereof |
| CN113005067A (en) * | 2021-03-31 | 2021-06-22 | 盐城维康生物科技有限公司 | Multifunctional composite probiotic preparation and preparation method thereof |
| CN113151056A (en) * | 2021-03-18 | 2021-07-23 | 仙乐健康科技股份有限公司 | Probiotic composition, preparation method and application thereof |
-
2022
- 2022-06-06 CN CN202210633339.XA patent/CN115154489B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1800688A1 (en) * | 2004-08-05 | 2007-06-27 | Anidral S.R.L. | Folic acid producing bifidobacterium bacterial strains, formulations and use thereof |
| CN105181963A (en) * | 2015-07-30 | 2015-12-23 | 西北农林科技大学 | Preparation method for ELISA detection kit of goat corynebacterium pseudotuberculosis antibodies |
| CN106176998A (en) * | 2016-07-15 | 2016-12-07 | 湖北省农业科学院畜牧兽医研究所 | A kind of compositions for treating goat skin submental lymph nodes abscess |
| CN110669697A (en) * | 2019-10-31 | 2020-01-10 | 江苏微康生物科技有限公司 | Lactobacillus casei for high yield of short-chain fatty acid, culture method and application thereof |
| CN113151056A (en) * | 2021-03-18 | 2021-07-23 | 仙乐健康科技股份有限公司 | Probiotic composition, preparation method and application thereof |
| CN113005067A (en) * | 2021-03-31 | 2021-06-22 | 盐城维康生物科技有限公司 | Multifunctional composite probiotic preparation and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| "Caseous lymphadenitis: Present and near forgotten from persistent vaccination?";P.A. Windsor et al.;《Small Ruminant Research》;第1-5页 * |
| "Interactions Between the Gut Microbiota and the Host Innate Immune Response Against Pathogens";Hong-Yu Cheng et al.;《Frontiers in Immunology》;第10卷;第1-11页 * |
| "山羊干酪性淋巴结炎病原的分离和鉴定";韦志锋 等;《中国动物检疫》;第28卷(第7期);第54-55和59页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115154489A (en) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114574390B (en) | Bifidobacterium longum subspecies infantis for relieving colonitis and application thereof | |
| CN110591945A (en) | Excellent lactobacillus reuteri for preventing ulcerative colitis | |
| CN114350578B (en) | Lactobacillus plantarum LP1Z for producing lysozyme and efficiently antagonizing multidrug-resistant helicobacter pylori and application thereof | |
| CN113122466B (en) | Enterococcus faecalis and application thereof | |
| CN109806389B (en) | Haemophilus parasuis trivalent inactivated vaccine and application thereof | |
| WO2017071346A1 (en) | Applications of bacteroides fragilis in resistance against aquacultural pathogenic bacteria | |
| CN115927102A (en) | Prisella megaterium, microbial inoculum, preparation method and application thereof | |
| CN113621533A (en) | Streptomyces rubiginosus Z1-26, microecological preparation and preparation method thereof | |
| CN112625979A (en) | Lactobacillus casei for resisting helicobacter pylori and application thereof | |
| CN115029260B (en) | Lactobacillus gasseri with anti-inflammatory and antioxidant properties and application thereof | |
| CN105779346B (en) | A kind of enterococcus faecium and its application of bacteriocinogeny | |
| CN113512516A (en) | Cooperative swine-origin lactobacillus mucosae and application thereof | |
| CN115154489B (en) | Multi-flora composite preparation and culture for treating sheep cheese lymphadenitis | |
| KR20130002533A (en) | Lactic acid bacteria group hindering growth of helicobactor pyloli | |
| CN115074286B (en) | Bacillus pumilus for antagonizing tinea pedis pathogenic fungi and application thereof | |
| CN114806953B (en) | Lactobacillus gasseri with effect of improving type 1 diabetes | |
| TW201016847A (en) | A strain of Lactobacillus plantarum and its use for inhibiting Helicobacter pylori growth | |
| KR20130002534A (en) | Lactic acid bacteria group hindering growth of helicobactor pyloli | |
| CN113018426B (en) | Combined strain for preparing haemophilus parasuis vaccine, octavalent inactivated vaccine and application thereof | |
| Al-Mathkhury et al. | Pathological study on Staphylococcus xylosus isolated from patients with urinary tract infections | |
| CN113018425B (en) | Mycoplasma hyopneumoniae and haemophilus parasuis bivalent pentavalent inactivated vaccine and application thereof | |
| CN112831442B (en) | Serum 14 type haemophilus parasuis with cross protection and application thereof | |
| US20220323518A1 (en) | Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis | |
| CN115161223A (en) | Acidophilic lactobacillus strain and application thereof | |
| US20220331381A1 (en) | Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |